Howard Davis joined Flagship Pioneering in 2018, bringing to the firm more than 15 years of experience in the biotech and pharmaceutical industry. At Flagship, Howard is focused on the management and expansion of Flagship’s portfolio of corporate innovation partnerships with leading life science companies.
Prior to joining Flagship, Howard spent five years at Biogen in roles of increasing responsibility across commercial, manufacturing, program leadership, and general management aspects of the business. His most recent role at Biogen was vice president & asset executive for BIIB092, an anti-tau mAb being developed in progressive supranuclear palsy and Alzheimer’s disease. Prior to joining Biogen, Howard worked for Novartis in Basel, Switzerland, first in corporate strategy and then in the company’s commercial organization, where he supported the launches of multiple block-buster drugs, including Gilenya and Lucentis. Howard has also served as a Boston-based project leader within the Boston Consulting Group’s Healthcare Practice, where he focused on commercial strategy and R&D for Fortune 500 clients.
Howard holds a B.Sc. in chemical engineering from Yale, as well as a Ph.D. in biomedical engineering from the Harvard-MIT Division of Health Sciences and Technology. Howard’s thesis research focused on approaches to enhance the transduction efficiency of viral-mediated gene therapies.